The trial supports the rapid expansion in indications for the use of SGLT2 inhibitors in a wide spectrum of HF (EMPEROR-Preserved28,29, EMPEROR-Reduced30,31, DAPA-HF32–34. Here, SLC5A2 is linked to hydrops fetalis.